

# Burkina Faso

## Tuberculosis profile

Population 2016

19 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	1.6 (0.97–2.4)	8.7 (5.2–13)
Mortality (HIV+TB only)	0.31 (0.19–0.44)	1.6 (1–2.4)
Incidence (includes HIV+TB)	9.4 (6.1–13)	51 (33–72)
Incidence (HIV+TB only)	0.87 (0.55–1.3)	4.7 (3–6.7)
Incidence (MDR/RR-TB)**	0.3 (0.18–0.41)	1.6 (0.97–2.2)

Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	0.46 (0.28–0.64)	2.9 (1.8–4.1)	3.4 (2.1–4.7)
Males	0.52 (0.32–0.73)	5.5 (3.4–7.7)	6.1 (3.7–8.4)
Total	0.99 (0.6–1.4)	8.5 (5.1–12)	9.4 (6.1–13)

TB case notifications, 2016

Total cases notified	5 918
Total new and relapse	5 677
- % tested with rapid diagnostics at time of diagnosis	<1%
- % with known HIV status	90%
- % pulmonary	83%
- % bacteriologically confirmed among pulmonary	81%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	60% (42–93)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.21 (0.11–0.34)

TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	492	10%
- on antiretroviral therapy	403	82%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			170 (120–220)
Estimated % of TB cases with MDR/RR-TB	2.1% (1.2–3)	14% (8.5–20)	
% notified tested for rifampicin resistance	<1%	58%	376
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 58, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 41, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	78%	5 553
Previously treated cases, excluding relapse, registered in 2015	72%	272
HIV-positive TB cases registered in 2015	70%	515
MDR/RR-TB cases started on second-line treatment in 2014	68%	34
XDR-TB cases started on second-line treatment in 2014		0

TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	23% (21–25)

TB financing, 2017

National TB budget (US\$ millions)	8.8
Funding source: 2% domestic, 23% international, 75% unfunded	


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence  
Notified (new and relapse)  
Incidence (HIV+TB only)

Notified cases by age group and sex, 2016




Treatment success rate (%)



New and relapse  
Retreatment, excluding relapse  
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)



Unfunded  
Funded internationally  
Funded domestically